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VaccinationAbstract In this study we aimed to determine the anti-tumor efﬁcacy of co-treatment of adoptively
transferred T cells with bone marrow either harvested from naı¨ve mice or G-CSF activated after
treatment with the anti-cancer drug cyclophosphamide (CTX) as a source enriched in stem cells.
CTX-treated Swiss Albino (CD-1) mice were injected with 2 · 105 Ehrlich ascetic carcinoma
(EAC) cell line and then adoptively transferred with in vitro co-activated T cells with or without
bone marrow one day post CTX treatment. All mice were vaccinated with tumor lysate and
Hiltonol. The results showed that co-transfer of activated T cells with bone marrow provided
the highest antitumor effect and induced marked increase in numbers of splenocytes, leucocytes
and bone marrow cells. Interestingly, T cells derived from EAC tumor-bearing host induced higher
effects than those from normal mice. In sum, our data suggest that combination of CTX and acti-
vated transferred T cells with bone marrow induces proliferation and expansion of immune cells,
which are functional and can be exploited in vivo to foster more effective antitumor adoptive
immunotherapy strategies.
ª 2015 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chemotherapy, immunotherapy, radiotherapy, hormone ther-
apy, gene therapy are the effective treatments for cancer
patients. Cytotoxic chemotherapy remains one of the most
widely available treatment options for cancer. Unfortunately,
the efﬁcacy of chemotherapy is limited and cures are rarely
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method, aimed at mobilizing the body’s immune cells to attack
tumor cells, but it is also rarely curative. The more recent
approach aim is looking into combining immunotherapy and
chemotherapy as a way to treat the cancer, largely because
the two forms of treatment are considered to be antagonistic
(Swan, 1981; De Pillis et al., 2005; Riker et al., 2007;
Rosenberg et al., 2008; Zouhari et al., 2013).
Chemotherapy can precondition for immunotherapy by
creating an environment for homeostatic lymphoproliferation
and eliminating some of the suppressive immune networks
(Young et al., 2009). Cytotoxic chemotherapeutic agents, such
as cyclophosphamide (CTX), can exert multiple effects on host
immune and non-immune cells and this action may be relevant
for the induction of an antitumor immune response (Emens
and Jaffee, 2005).
The DNA alkylating agent CTX is a well-known
chemotherapeutic agent used to treat various types of cancer
and is well known to potentiate the immune response by
removing Treg cells and blocking their function. In addition,
CTX is used clinically for the treatment of a variety of cancers
and autoimmune disease where until recently it was thought to
be immunosuppressive (Polak and Turk, 1974; Berd and
Mastrangelo, 1988; Dudley et al., 2002; Mitchell, 2003;
Ghiringhelli et al., 2004; Lutsiak et al., 2005). CTX is used
as an immunomodulatory agent in protocols for cancer vacci-
nation (Machiels et al., 2001; Hermans et al., 2003) and adop-
tive cell transfer (ACT) therapy (Salem et al., 2007, 2009, 2012;
Brode and Cooke, 2008).
The antitumor efﬁcacy of adoptively-transferred T cells in
response to vaccination can be effectively augmented by pre-
conditioning a host with lymphodepletion regimens such as
CTX (Wrzesinski and Restifo, 2005; Gattinoni et al., 2006;
Paulos et al., 2007; Salem et al., 2007, 2009, 2012). For
instance, Salem et al. (2009) revealed that the preconditioning
of a recipient host with CTX before adoptive T cell transfer
alone or followed by vaccination augmented both the quantity
and quality of the antitumor efﬁcacy of the adoptively trans-
ferred T cells, in particular when vaccination was performed
at both the lymphopenic and restoration phases post CTX
therapy. CTX induces an immunogenic apoptosis within the
tumor mass that acts as priming event for the induction of
antitumor immunity through the release of large amounts of
antigenic material and soluble factors recruiting and activating
dendritic cells (DCs) into the tumor bed, resulting in promo-
tion of the proliferation of effector T cells and abrogating
the function of regulatory T cells (Tregs) (Nakahara et al.,
2010).
Chemotherapy followed by administration of growth fac-
tors such as granulocyte colony stimulating factor (G-CSF)
is used for mobilization of hematopoietic stem cells (HSCs)
from bone marrow (BM) to circulation for correction of
leukopenia (Roberts, 2005; Winkler and Levesque, 2006;
Montgomery and Cottler-Fox, 2007) and selective mobiliza-
tion of dendritic cell (DC) progenitors in vivo which induced
to be functionally active mature DCs. Combinations of adop-
tive transfer of T cells and speciﬁc vaccination against the cog-
nate antigen can be envisaged to more enhancement of the
effectiveness of conventional cellular therapies (Stroncek
et al., 2012). Moreover, HSCs can augment the reconstitution
of the lymphoid compartment by increasing the expansion of
survival host cells and adoptively transferred T cells leadingto destroy large tumor burdens in the absence of cancer vacci-
nes (Wrzesinski et al., 2007).
G-CSF administration enhances both the induction of mye-
loid cell recovery or disease-related myelosuppression and the
mobilization of progenitor cells in individuals donating periph-
eral blood stem cells for transplantation (Rubinstein et al.,
2013). Besides, it augments post-CTX expansion of DCs, as
it acts on the residual progenitors in BM after CTX treatment
(Yankelevich et al., 2008). This notion is consistent with the
results of clinical studies showing increases in the DCs mobi-
lization into the peripheral blood of cancer patients after treat-
ment with CTX plus G-CSF (Ferrari et al., 2003). Moreover,
administration of G-CSF for 5 consecutive days markedly
increased the number of WBCs and neutrophils and this might
modulate the immunological network, activation of lympho-
cytes and granulocytes and shorten the duration of neutrope-
nia following chemotherapy (Disis, 2005; Salem and Cole,
2010; Su et al., 2012).
Based on previous study in chemo-immunotherapy, the
current study aimed to determine the anti-tumor efﬁcacy of
co-treatment of adoptively transferred T cells with bone mar-
row either harvested from naı¨ve mice or G-CSF activated after
treatment with the anti-cancer drug CTX as a source enriched
in stem cells. This study will open a new avenue to design
strategies for the combination of chemo-immunotherapy in
the clinical setting.Materials and methods
Mice
Female Swiss CD-1 mice were obtained from Company for
Biological Products and Vaccines (VACSERA), Cairo,
Egypt. Animals were 4–6 weeks old and weighed between
22–25 g at the beginning of the experiment.
They were handled and kept in a speciﬁc pathogen-free
facility at the Faculty of Science, Tanta University in accor-
dance with the ethical guidelines of the local Institutional
Animals Care and Use Committee. A total of 27 female CD-
1 mice randomly divided into nine groups of 3 each, including
one control group.
Reagents and cell lines
CTX (Sigma–Aldrich, USA) was reconstituted in PBS and fro-
zen until used. G-CSF was purchased from Biopharmaceutical
Co., Ltd., USA). Hiltonol, received as a gift from Dr. Andres
Salazar (Oncovir, Washington DC, USA), was dissolved in
phosphate-buffered saline (PBS) for intraperitoneal (i.p.) injec-
tion. Ehrlich Ascites Carcinoma (EAC) was purchased from
National Cancer Institute-Cairo, Egypt and maintained in
the ascitic form by the sequential passages in female CD-1
by means of bi-weekly i.p. injection of 2.5 · 105 tumor cells/-
mouse suspended in 0.1 ml PBS.
Preparation of tumor cell lysate
The ascitic ﬂuid was collected using a syringe and the EAC
cells were counted using a Neubauer hemocytometer and the
cell viability was determined using Trypan Blue dye exclusion
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of 5 · 106 cells/ml and stored at 80 C until use. Frozen
tumor cells were disrupted by four repetitive freeze–thaw
cycles. Lysis was monitored by light microscopy and larger
particles were removed by centrifugation (300g for 10 min at
4 C). Supernatants were then passed through a 0.2 lm ﬁlter,
protein concentration was determined by Bio-Rad protein
assay, and aliquots were frozen at 80 C until use.
In vitro T cells activation
Splenocytes were harvested from naı¨ve or EAC-bearing mice.
Single cell suspension was prepared under sterile conditions.
Cells were stimulated in vitro with 5 ng/ml Concanavalin A
(Con A) and 10 ng/ml interleukin 2 (IL-2) at 2.5 · 106 cells
/ml and incubated at 37 C and 5% CO2 for 48 h. Activated
cells were harvested and processed for the assay of interest.
Tumor challenge, chemotherapy and adoptive transfer of T-cells
According to Salem et al. (2007), naı¨ve mice were i.p. injected
with 0.25 · 106 EAC cells/mouse against control group
injected with PBS. On day 7, tumor-bearing mice were treated
with 4 mg /mouse CTX followed by adoptive transfer of
in vitro activated splenocytes from naı¨ve or tumor-bearing
mice by intravenous (i.v.) injection in mice tail against negative
control injected with PBS.
Adoptive transfer of BM, G-CSF treatment and vaccination
For adoptive transfer of exogenous BM (Ex. BM), donor
unfractionated BM cells were prepared from BM of naı¨ve
mice. Fresh BM cells were washed twice, resuspended in PBS
and transferred (5 · 106 cells/mouse), via lateral tail vein, into
tumor-bearing mice treated 2 d before with CTX and adop-
tively transferred with activated splenocytes. While in G-CSF
treatment, tumor-bearing mice treated 2 d before with CTX
and adoptively transferred with activated splenocytes were
subcutaneously (s.c.) administered with 5 lg/mouse G-CSF
for 5 successive days (Yankelevich et al., 2008). For tumor
lysate vaccination, tumor bearing mice treated with CTX
and adoptively transferred with activated splenocytes or BM
were vaccinated with 100 lg/mouse tumor lysate and 50 lg
Hiltonol. All mice were bled and sacriﬁced on day 15 and pre-
pared for different assays.
Statistical analysis
Numerical data obtained from each experiment were expressed
as mean ± SE and the statistical differences between experi-
mental and control groups were assessed using One-way
Analysis of Variance (ANOVA). The P values 60.05 were con-
sidered statistically signiﬁcant.
Results
Antitumor effect of BM progenitor cells
To evaluate antitumor efﬁcacy of treatment regimen consisting
of CTX preconditioning, adoptive transfer of activatedsplenocytes followed with BM cell injection and vaccination
with tumor lysate and Hiltonol, mice were i.p. injected with
PBS or CTX and then left without further treatment or adop-
tively transferred with activated splenocytes only or activated
splenocytes with Ex. BM injection or s.c. injection of G-CSF
daily for 5 consecutive days to mobilize endogenous stem
and myeloid cells. Three days post cell transfer; mice were vac-
cinated with tumor lysate and Hiltonol. Comparing to con-
trol CTX, adoptive transfer of activated splenocytes from
tumor-bearing mice (TSp) signiﬁcantly decreased fold of the
number of tumor cells to 0.09 · 106 (Fig. 1). Interestingly,
TSp treatment in combination with Ex. BM cells showed the
highest inhibitory effect on the fold of tumor cell count
(0.08 · 106) when compared to CTX control (Fig. 1).
Impact of BM cells on adoptive cell transfer and vaccination
The present results showed that CTX induced a rapid lym-
phopenia in BM cells, however, the number of BM cells signif-
icantly increased in this group after adoptive transfer of
activated splenocytes either from naı¨ve (NSp) or TSp
(Fig. 2). Moreover, administration of G-CSF with adoptive
transfer of activated NSp induced higher numbers of BM pro-
genitor cells but with no impact on the anti-tumor effects of
the activated TSp (Fig. 2).
Effect of BM cells on splenocytes and PBL upon
chemoimmunotherapy
To understand the impact of BM progenitor cells on the cellu-
larity of splenocytes and peripheral blood (PBL), mice were
i.p. injected with CTX (4 mg/mouse) and then left without fur-
ther treatment or adoptively transferred with activated spleno-
cytes with or without Ex. BM cell injection or s.c. injection of
G-CSF (5 lg/mouse) daily for 5 days after adoptive transfer of
splenocytes. Mice were vaccinated with tumor lysate plus
Hiltonol3 days post adoptive cell transfer. The results
revealed that adoptive transfer of activated NSp plus G-CSF
signiﬁcantly increased the number of leukocytes in spleen
(Fig. 3). Of interest, this effect was signiﬁcantly reversed upon
adoptive transfer of activated TSp (Fig. 3).
As shown in Fig. 4, the total number of leukocytes in PBL
showed a signiﬁcant decrease with the combination of adoptive
T-cell transfer with G-CSF, whereas injection with Ex. BM
had no signiﬁcant effect.
NSp plus Ex. BM injection induced a marked increase in
the number of lymphocytes in PBL (Fig. 5). The number of
neutrophils in PBL was decreased in all groups, but it was
markedly decreased by the injection of NSp alone, TSp alone
or NSp plus G-CSF (Fig. 6). There was, however, a signiﬁcant
decrease in the number of PBL monocytes in NSp, NSp plus
G-CSF, NSp plus Ex. BM, TSp and TSp plus G-CSF, (Fig. 7).
Discussion
The present study revealed that adoptive transfer of activated
T cells obtained from EAC-bearing mice with vaccination can
provide high antitumor effect and induce marked increase in
number of BM cells. This observation is in line with our recent
studies that reported conditioning of the recipient host with a
lymphodepletion regimen of CTX before adoptive T cell
Figure 1 Antitumor effect of adoptive transfer of both endogenous or exogenous BM cells and activated splenocytes of naı¨ve or tumor
bearing mice with vaccination. Mice were i.p. injected with PBS or CTX (4 mg/mouse) and then left without further treatment (groups:
PBS and CTX) or adoptively transferred with activated splenocytes only or activated splenocytes with bone marrow or s.c. injection of G-
CSF (5 lg/mouse) daily for 5 d of adoptive transfer of splenocytes. Mice were vaccinated with tumor lysate and Hiltonol on day 3 of cell
transfer. Mice were sacriﬁced on day 7 post PBS or CTX treatments to determine the total number of tumor cells. *P 6 0.05 as compared
with CTX (positive control).
Figure 2 Effect of co-treatment with BM and adoptive transfer of activated splenocytes plus vaccination on BM progenitor cells. Mice
were i.p. injected with PBS or CTX (4 mg/mouse) and then left without further treatment (groups: PBS and CTX) or adoptively
transferred with activated splenocytes only or activated splenocytes with bone marrow or s.c. injection of G-CSF (5 lg/mouse) daily for
5 d of adoptive transfer of splenocytes. Mice were vaccinated with tumor lysate and Hiltonol on day 3 of cell transfer. Mice were
sacriﬁced on day 7 post PBS or CTX treatments to determine the total number of BM cells. *P< 0.05; **P< 0.01, as compared with CTX
(positive control).
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vival of the transferred cells. In addition, further enhancement
was revealed when this treatment is followed by vaccination
with tumor antigens in combination with a potent immune
adjuvant (Salem and Cole, 2010).
Adoptive transfer of ex vivo re-stimulated tumor-reactive
memory T cells from BM of metastasized breast cancer
patients has been found to induce tumor antigen-reactive
type-1 T cells in PBL (Schuetz et al., 2009). Moreover, tumor
associated antigens from tumor cells circulating in the blood
can reach spleen and BM, where resident DCs can process
and cross-present them to prime T cells leading to the genera-
tion of effector and memory cells which can either destroy
tumor cells or control them in a state of tumor dormancy(Schirrmacher et al., 2003). In addition, combinations of adop-
tive transfer of T cells and speciﬁc vaccination against the cog-
nate antigen can be envisaged to more enhancement of the
effectiveness of conventional cellular therapies (Stroncek
et al., 2012).
Interestingly, our data further showed that combinatorial
treatment of adoptive transfer of activated TSp and Ex. BM
cells induced the highest antitumor effect. Similarly, combined
adoptive transfer of activated NSp and G-CSF signiﬁcantly
increased number of splenocytes and BM cells by enhancing
their proliferation and expansion, whereas this treatment with-
out BM showed a slight increase in the cellularity of spleen and
BM cells. This may be due to activation of BM with G-CSF
which induces proliferation of BM progenitor cells and their
Figure 3 Effect of co-treatment with BM and adoptive transfer of activated splenocytes plus vaccination on leucocytes of spleen. Mice
were i.p. injected with PBS or CTX (4 mg/mouse) and then left without further treatment (groups: PBS and CTX) or adoptively
transferred with activated splenocytes only or activated splenocytes with bone marrow or s.c. injection of G-CSF (5 lg/mouse) daily for
5 d of adoptive transfer of splenocytes. Mice were vaccinated with tumor lysate and Hiltonol on day 3 of cell transfer. Mice were
sacriﬁced on day 7 post PBS or CTX treatments to determine the total number of leucocytes of spleen. *P< 0.05; **P< 0.01, as
compared with CTX (positive control).
Figure 4 Effect of combination treatment of endogenous or exogenous BM cells and adoptive transfer with vaccination on leucocytes of
PBL. Mice were i.p. injected with PBS or CTX (4 mg/mouse) and then left without further treatment (groups: PBS and CTX) or
adoptively transferred with activated splenocytes only or activated splenocytes with bone marrow injection or s.c. injection of G-CSF
(5 lg/mouse) daily for 5 d of adoptive transfer of splenocytes. Mice were vaccinated with tumor lysate and Hiltonol on day 3 of cell
transfer. Mice were sacriﬁced on day 7 post PBS or CTX treatments to determine the number of leucocytes of PBL. *P< 0.05; **P< 0.01,
as compared with CTX (positive control).
Figure 5 Co-treatment effect of endogenous or exogenous BM cells and adoptive transfer with vaccination on lymphocytes of PBL.
Mice were i.p. injected with PBS or CTX (4 mg/mouse) and then left without further treatment (groups: PBS and CTX) or adoptively
transferred with activated splenocytes only or activated splenocytes with bone marrow injection or s.c. injection of G-CSF (5 lg/mouse)
daily for 5 d of adoptive transfer of splenocytes. Mice were vaccinated with tumor lysate and Hiltonol on day 3 of cell transfer. Mice
were sacriﬁced on day 7 post PBS or CTX treatments to determine the number of lymphocytes of PBL. ***P 6 0.01 as compared with CTX
as a positive control.
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Figure 6 Adoptive transfer effect of activated splenocytes and endogenous or exogenous BM cells with vaccination on neutrophils of
PBL. Mice were i.p. injected with PBS or CTX (4 mg/mouse) and then left without further treatment (groups: PBS and CTX) or
adoptively transferred with activated splenocytes only or activated splenocytes with bone marrow injection or s.c. injection of G-CSF
(5 lg/mouse) daily for 5 d of adoptive transfer of splenocytes. Mice were vaccinated with tumor lysate and hilta Hiltonol on day 3 of cell
transfer. Mice were sacriﬁced on day 7 post PBS or CTX treatments to determine number of neutrophils of PBL. *P< 0.05; **P< 0.01,
as compared with CTX (positive control).
Figure 7 Co-treatment effect of endogenous or exogenous BM cells and adoptive transfer of activated splenocytes with vaccination on
monocytes of PBL. Mice were i.p. injected with PBS or CTX (4 mg/mouse) and then left without further treatment (groups: PBS and
CTX) or adoptively transferred with activated splenocytes only or activated splenocytes with bone marrow injection or s.c. injection of G-
CSF (5 lg/mouse) daily for 5 d of adoptive transfer of splenocytes. Mice were vaccinated with tumor lysate and Hiltonol on day 3 of cell
transfer. Mice were sacriﬁced on day 7 post PBS or CTX treatments to determine the number of monocytes in PBL. ***P 6 0.01 as
compared with CTX (positive control).
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of Nervi et al. (2006), and Montgomery and Cottler-Fox
(2007) as they used CTX in combination with growth factors
such as G-CSF for the mobilization of HSC from BM to cir-
culation. Also, Domschke et al. (2013) showed that the BM
of breast cancer patients harbors tumor-reactive memory T
cells (TCs) with therapeutic potential. Moreover, HSCs can
augment the reconstitution of the lymphoid compartment by
increasing the expansion of survival host cells and adoptively
transferred T cells leading to destroy large tumor burdens in
the absence of cancer vaccines (Wrzesinski et al., 2007).
BM which is a crucial organ in mature T-cell trafﬁc, con-
tributes greatly to long-term cytotoxic memory as well as to
homeostatic regulation of peripheral CD8 T cell numbers,
can prime naı¨ve T cells and recruit effector T cell (Cassese
et al., 2007; Parretta et al., 2005 and Parretta et al., 2008). In
line with this notion, the current study showed that BM has
a vital role in adoptive transfer of T cell and vaccination. So,
in peripheral blood, the number of leucocytes was signiﬁcantlydecreased with combination therapy of BM cells with ACT
from naı¨ve or EAC-bearing mice. However, this treatment
showed high increase in the number of lymphocytes, this
may be due to differentiation of mobilized BM cells into lym-
phocytes to recover CTX-induced leucopenia, while there is
decrease in the number of neutrophils and monocytes as they
may need more time to recover.
Taken together, combination of chemotherapy with ACT
from tumor-bearing mice with vaccination constitutes a potent
antitumor therapy and this therapy provides more efﬁcacious
antitumor responses when it is combined with BM cells.
In summary, our data suggested that combining lymphode-
pletion, adoptive T cell therapy, vaccination, and BM cells
may provide a useful design of anti-cancer immunotherapy
regimens. This combined therapy was strong enough to gener-
ate tumor-free mice in the EAC model and immunosuppressive
networks. Interestingly, BM progenitor cells (exogenous or
endogenous) present a new strategy for combined chemo-
immunotherapy to optimize the cellular product, including
102 M.L. Salem et al.modulation of the host environment, in particular by lym-
phodepletion and may give opportunity to activate T cells out-
side the tolerating environment of the host.
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